After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Leading life science and deep tech investors IQ Capital, Cancer Research Horizons, the US National Brain Tumor Society’s Brain Tumor Investment Fund, AIN Ventures and the University of Edinburgh’s ...

On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...

New tools and products developed by biotechnologists are useful in research, agriculture, industry and the clinic. Optical tissue clearing allows high-resolution microscopy imaging of biological ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Stem-cell research is the area of research that studies the properties of stem cells and their potential use in medicine. As stem cells are the source of all tissues, understanding their ...

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...

A clear picture of Biogen's perception among financial experts ... Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders ...